1 Min Read
March 29 (Reuters) - Armo Biosciences Inc:
* ARMO BIOSCIENCES ENROLLS FIRST PATIENT IN THE CYPRESS 2 TRIAL EVALUATING AM0010 IN NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.